Bio-Rad Laboratories (BIO) Current Deferred Revenue (2010 - 2022)

Bio-Rad Laboratories (BIO) has 13 years of Current Deferred Revenue data on file, last reported at $52.2 million in Q4 2022.

• Current Deferred Revenue for Q4 2022 came in at $52.2 million, down 26.48% year-over-year; the trailing twelve-month figure through Dec 2022 was $52.2 million (down 26.48% YoY), and the FY2022 annual result was $52.2 million, down 26.48% from the prior year.
• Current Deferred Revenue slipped to $52.2 million in Q4 2022 per BIO's latest filing, from $71.0 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $71.0 million in Q4 2021 and troughed at $26.9 million in Q4 2018.
• A 5-year average of $44.5 million and a median of $42.5 million in 2020 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2021 and 2022: Current Deferred Revenue surged 67.06% in 2021, then declined 26.48% in 2022.
• A 5-year view of Current Deferred Revenue shows it stood at $26.9 million in 2018, then gained by 25.24% to $33.7 million in 2019, then advanced by 25.98% to $42.5 million in 2020, then surged by 67.06% to $71.0 million in 2021, then decreased by 26.48% to $52.2 million in 2022.
• Business Quant data shows BIO's Current Deferred Revenue at $52.2 million in Q4 2022, $71.0 million in Q4 2021, and $42.5 million in Q4 2020.